NCT00068614已完成1 期
A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.
详细描述
OBJECTIVES:
Primary
- Determine the safety of HER-2 protein AutoVac™ in women with breast cancer.
Secondary
- Determine the ability of this drug to bypass the tolerance to the HER-2 self-protein by raising HER-2 antibodies in these patients.
- Determine the kinetics of the immune response to HER-2/neu in patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV MelanomaMelanoma (Skin)NCT00010309Genzyme, a Sanofi Company
已完成
1 期
Vaccine Therapy in Treating Patients With Stage IV Head and Neck CancerHead and Neck CancerMetastatic CancerNCT00021424National Institute on Deafness and Other Communication Disorders (NIDCD)
已完成
1 期
Vaccine Therapy in Treating Patients With Stage IV MelanomaMelanoma (Skin)NCT00023647Mannkind Corporation26
已完成
1 期
Vaccine Therapy in Treating Patients With Stage IV MelanomaMelanoma (Skin)NCT00033228Mannkind Corporation19
Unknown
1 期
Vaccine Therapy in Treating Patients With Metastatic MelanomaMelanoma (Skin)NCT00022568Herbert Irving Comprehensive Cancer Center